Management of Febrile Neutropenia – a German Prospective Hospital Cost Analysis in Lymphoproliferative Disorders, Non-Small Cell Lung Cancer, and Primary Breast Cancer

Angela Ihbe-Heffinger a,b, Bernadette J. Paessens a, Christoph von Schilling c,d, Margarita Shlaen e, Nina Gottschalk b, Karin Berger f, Rudolf Bernard h, Marion Kiechle e, Christian Peschel e, Volker R. Jacobs a,b, g

a Krankenhausapotheke, b Frauenklinik, c Abteilung für Transfusionsmedizin und Hämostaseologie, Klinikum der Universität München, d Medizinische Klinik III, Klinikum Freising, e Health Economics und Outcomes Research, IMS HEALTH GmbH München, f Abteilung für Transfusionsmedizin und Hämostaseologie, Klinikum der Universität München, g Frauenklinik, Universitätsklinikum Köln Köln, Germany

Summary

Background: Febrile neutropenia/leukopenia (FN/FL) is the most frequent dose-limiting toxicity of myelosuppressive chemotherapy, but German data on economic consequences are limited. Patients and Methods: A prospective, multicentre, longitudinal, observational study was carried out to evaluate the occurrence of FN/FL and its impact on health resource utilization and costs in non-small cell lung cancer (NSCLC), lymphoproliferative disorder (LPD), and primary breast cancer (PBC) patients. Costs are presented from a hospital perspective. Results: A total of 325 consecutive patients (47% LPD, 37% NSCLC, 16% PBC; 46% age ≥ 65 years) with 68 FN/FL episodes were evaluated. FN/FL occurred in 22% of the LPD patients, 8% of the NSCLC patients, and 27% of the PBC patients. 55 FN/FL episodes were associated with at least 1 hospital stay (LPD n = 34, NSCLC n = 10, PBC n = 11). Mean (median) cost per FN/FL episode requiring hospital care amounted to € 3,950 (€ 2,355) and varied between € 3,056 (LPD, € 3,627 for NSCLC, and € 3,950 for PBC) per FN/FL episode or performed hospital care amounted to € 3,950 (€ 2,355) and varied between € 4,808 (€ 3,056) for LPD, € 3,627 (€ 2,255) for NSCLC, and € 1,827 (€ 1,969) for PBC patients. 12 FN/FL episodes (LPD n = 9, NSCLC n = 3) accounted for 60% of the total expenses. Main cost drivers were hospitalization and drugs (60% and 19% of the total costs). Conclusions: FN/FL treatment has economic relevance for hospitals. Costs vary between tumour types, being significantly higher for LPD compared to PBC patients. The impact of clinical characteristics on asymmetrically distributed costs needs further evaluation.

Keywords
Costs and cost analysis · Neutropenia · Leukopenia · Health resources · Combined antineoplastic treatment protocols · Adverse effects

Schlüsselwörter
Kosten und Kostenanalyse · Neutropenie · Leukopenie · Gesundheitsressourcen · Kombinierte antitumoröse Behandlungsprotokolle · Nebenwirkungen

Zusammenfassung
Introduction

Febrile neutropenia (FN) is considered a potential life-threatening emergency in patients receiving myelosuppressive chemotherapy (CTX) for cancer. As patients with a reduced white blood cell count (WBC) are especially vulnerable to all kinds of infections [1] and fever is often the only warning sign, immediate medical attention is necessary to prevent infection as early as possible [2]. Therefore, FN usually leads to hospitalization and treatment with broad spectrum antibiotics [3]. The result is often a dose limitation up to a delay of the next CTX cycle [4, 5].

Aside from the clinical consequences, routine management of neutropenia and FN has a considerable economic impact, particularly in the inpatient setting [6]. Currently, the existing health economic literature mainly originates from the United States. Mean costs for neutropenia-related care there recently were $12,397 per patient [7]. With $19,110, mean costs per episode associated with the more severe FN can be markedly higher [8]. Moreover, cancer type and level of care seem to have a substantial impact on FN management costs. In a pilot study with community oncology cancer patients, total direct inpatient costs were on average $17,869 for lymphoma compared to $10,354 for breast cancer patients [9]. Direct costs for outpatients were remarkably lower (lymphoma: $5,704; breast cancer: $1,094).

American data tend to report substantially higher costs than those for Europe. A Spain retrospective study estimates € 3,841 mean direct cost per episode attributable to FN [10]. Although pressure on health care budgets is constantly rising, especially for Germany microeconomic data on supportive care interventions are very limited. As supportive care issues are especially large in patients with non-small cell lung cancer (NSCLC), lymphoproliferative diseases (LPD), and primary breast cancer (PBC), the occurrence of FN and its impact on health resource utilization and costs were therefore prospectively investigated in this group of patients in a non-interventional setting.

Patients and Methods

Study Design

This was a subgroup analysis of a prospective, longitudinal, multicentre, observational study [11] with consecutive patient recruiting between January 2005 and December 2006 in 4 Bavarian hospitals in Germany (n = 2 universities; n = 2 standard care). Centres were selected to be experienced in the administration of CTX and represent all levels of current hospital cancer care. Patient follow-up lasted until June 2007. Analysis of resource consumption and costs was performed from the hospital provider’s perspective. The study was approved by the hospitals’ local ethics committees, and written informed consent was obtained from all patients.

Patients

The study population consisted of patients fulfilling the following inclusion criteria: 1st or 2nd line (immuno)-CTX for NSCLC, LPD, or PBC. PBC patients had to be undergoing an anthracycline- or taxane-based (neo) adjuvant schedule. To avoid inclusion of patients whose CTX was only initiated at study site, patients had to be scheduled for at least 2 CTX visits. Patients receiving myeloablative CTX with stem cell support were excluded, as were those who were unable to participate in patient interviews for linguistic or cognitive reasons. Recurrent enrolment was possible.

Data Collection

Basic demographics and clinical history at first enrolment as well as anticancer treatment characteristics and toxicity-associated resource usage were collected by pre-planned chart abstraction. Occurrence and severity of CTX-induced toxicity were recorded at each CTX visit using a structured interview or by telephone after the final CTX visit according to the NCI CTCAE v3.0 and the causality criteria of the World Health Organisation Uppsala Monitoring Centre (WHO-UMC) [12].

Laboratory tests including WBC were recommended on a weekly basis. In the case of fever, outpatients were advised to contact their physician for assessment of haematological counts. If nadir monitoring was provided by external institutions, a written demand requesting to disclose nadir blood counts was issued via the patient. FN was incorporated into analysis as a composed variable. FN was defined as fever ≥ 38°C and an absolute neutrophil count (ANC) < 1 x 10⁹/l. If nadir ANC was unavailable, febrile leukopenia (FL) was assessed (leukocytes < 2 x 10⁹/l and fever ≥ 38°C). Granulocyte colony-stimulating factor (G-CSF) use was considered as prophylaxis if started between 24 h and 120 h after CTX [13].

To evaluate costs from the hospital provider’s perspective, the quantified resource use associated with an FN/FL episode was multiplied by the respective unit cost for each resource. Cost data sources used for calculation were as follows: i) Drugs and blood products: local actual costs for supply (Hospital Pharmacy and Transfusion Unit of the Klinikum rechts der Isar (MRI) in 2007; ii) Diagnostics: DKG-NT (Deutsche Krankenhausgesellschaft-Normaltarif; Standard Rate of the German Hospital Federation 2005, column 7: full cost); iii) Hospitalization: local actual mean costs per day based on internal accounting data in 2007 (€ 259.50 for normal care, € 805.00 for intensive care, and € 106.50 for outpatient or day care).

Fig. 1. Study flow chart.
Cost Analysis of Febrile Neutropenia

Onkologie 2011;34:241–246

243

summarized in Table 1. They differ markedly depending on tumour type. PBC patients were younger than patients with LPD or NSCLC. Nobody presented with ECOG ≥ 2, and only 1 patient with stage III/IV disease. In contrast, all NSCLC patients with FN/FL had an advanced tumour stage. None of the NSCLC patients received G-CSF prophylaxis, while 43% of LPD and 21% of PBC cases did.

Resource Usage during FN/FL-Associated Hospital Treatment

Data on the level of hospital care during FN/FL episodes are summarized in Table 2. In total, 68 FN/FL episodes were observed; 13 episodes (29%) were resolved without, 55 (81%) with additional hospital care. Inpatient management with a 7-day median length of stay was more frequent than outpatient or day care (72 vs. 20%). Intensive care was necessary in 5 episodes (7%). Three episodes could not be included in the detailed analysis of resource usage because of missing data (Fig. 2). A total of 88% of episodes were treated with drug therapy. Frequently used drugs were antibiotics (83%), antifungicides (29%), G-CSF (27%), and virustatics (19%). Blood products including red blood cells, platelets, fresh

Table 1. Febrile neutropenia/febrile leukopenia (FN/FL) patient characteristics at 1st enrolment and anticancer treatment

<table>
<thead>
<tr>
<th></th>
<th>Total (n = 58)</th>
<th>NSCLC (n = 9)</th>
<th>LPD (n = 35)</th>
<th>PBC (n = 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females, n (%)</td>
<td>33 (57)</td>
<td>3 (33)</td>
<td>16 (46)</td>
<td>14 (100)</td>
</tr>
<tr>
<td>Age, years</td>
<td>58.1 ± 14.5 (54.3–61.9)</td>
<td>60.7 ± 8.1 (54.5–66.9)</td>
<td>59.0 ± 16.5 (53.3–64.6)</td>
<td>54.1 ± 12.4 (47.0–61.3)</td>
</tr>
<tr>
<td>Age ≥ 65 years, n (%)</td>
<td>22 (38)</td>
<td>3 (33)</td>
<td>16 (46)</td>
<td>3 (21)</td>
</tr>
<tr>
<td>Height, cm</td>
<td>168.9 ± 8.2 (166.8–171.1)</td>
<td>170.7 ± 8.0 (164.5–176.8)</td>
<td>170.0 ± 8.1 (167.2–172.8)</td>
<td>165.1 ± 7.8 (160.6–169.6)</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>72.6 ± 12.3 (69.4–75.9)</td>
<td>70.3 ± 8.0 (64.2–76.5)</td>
<td>73.6 ± 12.2 (69.3–77.8)</td>
<td>71.8 ± 15.2 (63.0–80.6)</td>
</tr>
<tr>
<td>ECOG ≥ 2, n (%)</td>
<td>6 (10)</td>
<td>2 (22)</td>
<td>4 (11)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Tumour stage ≥ III, n (%)</td>
<td>27 (47)</td>
<td>9 (100)</td>
<td>17 (49)</td>
<td>1 (7)</td>
</tr>
<tr>
<td>2nd line CTX, n (%)</td>
<td>9 (15)</td>
<td>2 (20)</td>
<td>6 (17)</td>
<td>1 (7)</td>
</tr>
<tr>
<td>CTX regime, n (%)</td>
<td>9 (80)</td>
<td>19 (54)</td>
<td>5 (36)</td>
<td></td>
</tr>
<tr>
<td>Overall CTX cycles</td>
<td>4.9 ± 1.9 (2.7–5.5)</td>
<td>4.3 ± 2.4 (3.5–5.1)</td>
<td>5.2 ± 1.4 (4.4–6.0)</td>
<td></td>
</tr>
<tr>
<td>G-CSF prophylaxis</td>
<td>18 (31)</td>
<td>0</td>
<td>15 (43)</td>
<td>3 (21)</td>
</tr>
</tbody>
</table>

*Mean ± standard deviation (95% confidence interval).

aLPD: CLL – Binet stage A was transformed to Ray stage 0, none of the CLL patients had tumour stage > Binet A; PBC: t-stage

bPercentage of n = 59 CTX lines
cn = 4 missing.

dStart of G-CSF treatment ≥ 24 h and ≤ 120 h after CTX [13].

fPlatinum-based.

gCHOP-like.

hAnthracyclin + taxane-based.

NSCLC = Non-small cell lung cancer; LPD = lymphoproliferative diseases; PBC = primary breast cancer; CTX = chemotherapy; CLL = chronic lymphocytic leukaemia; G-CSF = granulocyte-colony stimulating factor.

Table 2. Level of care during febrile neutropenia/febrile leukopenia (FN/FL) episodes (all FN/FL episodes: n = 68, FN: n = 28; FL: n = 40)

<table>
<thead>
<tr>
<th></th>
<th>FN/FL episodes with hospital treatment, n (%)</th>
<th>Length of hospital stay* days, mean ± SD (95% CI)</th>
<th>Median (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>55 (81)</td>
<td>8.8 ± 5.9 (7.1–10.5)</td>
<td>7 (1–30)</td>
</tr>
<tr>
<td>Inpatient care</td>
<td>49 (72)</td>
<td>10.0 ± 11.5 (3.3–25.3)</td>
<td>9 (2–30)</td>
</tr>
<tr>
<td>Intensive care</td>
<td>5 (7)</td>
<td>8.2 ± 5.1 (6.7–9.7)</td>
<td>7 (1–24)</td>
</tr>
<tr>
<td>Normal care</td>
<td>46 (65)</td>
<td>5.6 ± 1 (1–2)</td>
<td>1 (1–4)</td>
</tr>
<tr>
<td>Outpatient/day care</td>
<td>15 (20)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Re-hospitalisation or prolonged hospitalization due to FN/FL.

Statistical Analysis

Data were analyzed using the software Microsoft Excel 2002 and SAS version 8.0 (SAS Institute Inc., Cary, NC, USA). For descriptive purposes, frequency distribution of study parameters as well as mean, standard deviation (SD), median, and range were calculated. The 95% confidence interval (CI) was given when statistically appropriate.

Results

Study Population and Occurrence of FN/FL

A total of 325 patients including 338 CTX lines (n = 130 NSCLC, n = 156 LPD, n = 52 PBC) were evaluable for analysis (Fig. 1). Sixty-eight FN/FL episodes were observed in 59 CTX lines (17.5%); 15.3% (n = 9) received a 2nd line CTX, n = 6 for LPD treatment. Stratified according to tumour type FN/FL episodes occurred in 10 NSCLC, 35 LPD, and 14 PBC CTX lines (7.7, 22.4, and 26.9%, respectively). Seven cases had more than 1 FN/FL episode (1 NSCLC, 5 LPD, 1 PBC). Grade 4 neutropenia/leukopenia was documented in 67.6% of FN/FL episodes (NSCLC, 36.4%, LPD 76.2%, PBC 66.7%). FN/FL patients and anticancer treatment characteristics are

Resource Usage during FN/FL-Associated Hospital Treatment

Data on the level of hospital care during FN/FL episodes are summarized in Table 2. In total, 68 FN/FL episodes were observed; 13 episodes (29%) were resolved without, 55 (81%) with additional hospital care. Inpatient management with a 7-day median length of stay was more frequent than outpatient or day care (72 vs. 20%). Intensive care was necessary in 5 episodes (7%). Three episodes could not be included in the detailed analysis of resource usage because of missing data (Fig. 2). A total of 88% of episodes were treated with drug therapy. Frequently used drugs were antibiotics (83%), antifungicides (29%), G-CSF (27%), and virustatics (19%). Blood products including red blood cells, platelets, fresh
Although European health care systems differ, direct cost estimates of FN management are similar to our results. From a Dutch health care payer’s perspective, €3,290 per FN episode were established for SCLC patients [15,17]. Similarly to our results, a recently published Spanish retrospective study reports FN-related costs depending on tumour type [10]. Costs were highest if NHL was the underlying cancer (€4,514). For patients with lung and breast cancer, FN-related costs were considerably cheaper (€3,310 and €3,518; significantly for lung cancer patients).

In contrast to the mixed breast cancer population (40% stage IV; 39% > 60 years) investigated by Mayordomo et al. [10], we studied a cohort of PBC patients (7% ≥ stage III; 21% > 65 years). Surprisingly, costs per FN episode were reduced by half (€1,827) and differed significantly from our LPD cohort (€4,808). Similar cost estimates were found in a PCB cohort with 1–3 positive axillary lymph nodes, including 12 toxicity-associated re-hospitalisations with mean direct costs of €2,209 [18]. Therefore, besides tumour type, other patient- or treatment-related factors seem to influence FN-associated costs.

With approximately 23% of FN episodes producing 60% of the total economic burden, cost distribution is asymmetric. Therefore, mean FN-associated costs (€3,950) markedly differ from median costs (€2,355). Typically, mean costs serve as cost estimates in health economic models. Overestimation of actual cost-effectiveness could be the consequence. This may be crucial when results of health economic models influence reimbursement decisions and supportive care guidelines.

Since toxicity management was covered mainly by the participating study centres, downstream resource consumption (e.g. consultation of a general practitioner) was estimated to be low. A considerable proportion of cancer patients in Germany receives an obligatory sick leave for the entire CTX period or is already retired. Earlier data therefore had shown a small number of workdays lost attributable to CTX-induced toxicity [14]. That is why FN-associated indirect costs were not considered in this study.

**Fig. 2.** Febrile neutropenia/febrile leukopenia (FN/FL) episodes with resource use during hospital treatment (n = 52; n = 3 episodes with missing data regarding detailed resource use).

**Fig. 3.** Frequency distribution of febrile neutropenia/febrile leukopenia (FN/FL)-associated costs per episode (n = 52; n = 3 episodes with missing data regarding detailed resource use); median €2,355.

**Cost of FN Management**

Full published data on the burden of disease in Germany after the introduction of German Diagnosis-Related Groups (G-DRGs) in 2004 are not available. From a 1998 German health insurance perspective, €2,396 mean FL-associated costs occurred in 13 small cell lung cancer patients (SCLC), as were €3,192 in 26 non-Hodgkin’s lymphoma (NHL) patients per episode with neutropenia, fever, and/or infections [15,16].

Frozen plasma, albumin, and antithrombin III were reported in 29% of episodes. The most relevant diagnostic procedure was microbiology testing (79%).

**Costs**

Costs associated with the management of an FN/FL episode are presented in Table 3, stratified according to cancer type. Mean (median) cost per episode totalled €3,950 (€2,355); 95% CI: €2,568–5,332. Cost drivers are basic performance of the department (hospitalization) and drugs. They account for 60 and 19%, respectively, of the total mean cost. For patients with LPD, total mean costs are significantly higher than for PCB patients (€4,808 vs. €1,827). This is mainly due to significantly higher costs for drugs, blood products, and microbiology testing. Mean total costs of €3,627 per FN/FL episode occurred for NSCLC patients. Frequency distribution of FN/FL-associated management costs is asymmetric; 23% of episodes (n = 9 LPD; n = 3 NSCLC) generated 60% of the total economic burden in the observed cohort (Fig. 3). There were no PCB patients in this high-cost subgroup.

**Discussion**

This study confirms that FN/FL is an expensive complication of myelosuppressive CTX, also in Germany. Compared to the management of CTX-induced nausea and vomiting, mean costs per cycle or episode with toxicity are considerably higher (€61 vs. €3,950) from a hospital perspective [14].

Full published data on the burden of disease in Germany after the introduction of German Diagnosis-Related Groups (G-DRGs) in 2004 are not available. From a 1998 German health insurance perspective, €2,396 mean FL-associated costs occurred in 13 small cell lung cancer patients (SCLC), as were €3,192 in 26 non-Hodgkin’s lymphoma (NHL) patients per episode with neutropenia, fever, and/or infections [15,16].
Referring to sensitivity analyses performed for the underlying study [19], cost results were most sensitive regarding costs of hospital basic services (maximum variation: ±14%).

Clinical Implications and Further Research

Although studies from the United States consistently report higher FN management costs, frequency distribution of FN-associated length of stay – which directly corresponds to FN-associated hospitalization costs – was shown to be similarly asymmetric [8]. As a result, predictors for high FN management costs should contribute to improve cost-effectiveness of current supportive care strategies, irrespective of differences in health care systems. Patient and treatment characteristics such as age, leukaemia, hypovolaemia, co-morbidities, and infectious complications are associated with increased mortality, length of stay, and cost due to FN [8, 20, 21]. In an additional generalized linear regression model of this data, grade of neutropenia/leukopenia and CTX line were associated with higher FN management costs. Further confirmatory research with higher sample sizes is warranted. In conclusion, this study confirms that FN/FL has considerable economic consequences for German hospitals. Costs vary between tumour types, being significantly higher for LPD compared to PBC patients. Main cost drivers are hospitalization and drugs. To improve cost-effectiveness of current supportive care strategies, the impact of clinical characteristics on asymmetrically distributed FN management costs needs further evaluation.

Acknowledgements

This subanalysis was supported by Amgen GmbH, München, Germany, the underlying investigator-sponsored study [19] was supported by Lilly Deutschland GmbH, Bad Homburg, Germany. We thank Dirk Eheberg for his editorial assistance.

Disclosure Statement

Angela Ihbe-Heffinger: Research grant (Lilly, Amgen, Germany); honoraria (Amgen, Germany). Volker R. Jacobs: Research grant (Amgen, Germany). All other authors declared no conflict of interests.

References


